Navigation Links
Emdeon Inc. Commences U.S. Initial Public Offering of Class A Common Stock
Date:7/28/2009

NASHVILLE, Tenn., July 28 /PRNewswire/ -- Emdeon Inc. (the "Company") today announced the launch of its initial public offering in the United States of 21,450,000 shares of its Class A common stock. Of the shares being offered, 10,725,000 are being offered by the Company and 10,725,000 are being offered by selling stockholders. The initial public offering price is expected to be between $13.50 and $15.50 per share of Class A common stock. The shares have been approved for listing on the New York Stock Exchange under the ticker symbol "EM." The underwriters have the option to purchase from the selling stockholders up to an additional 3,217,500 shares of Class A common stock, on the same terms and conditions, to cover over-allotments, if any.

The Company intends to use approximately $5.3 million of the net proceeds from the offering received to repurchase ownership interests in its operating subsidiary held by certain members of management with the remainder used for general corporate purposes, which may include the repayment of indebtedness and future acquisitions. The Company will not receive any of the proceeds from the offering of the Class A common stock by the selling stockholders.

Morgan Stanley, Goldman, Sachs & Co., UBS Investment Bank and Barclays Capital will act as book- running managers of the offering.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described above, nor shall there be any sale of such shares of Class A common stock in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering of these securities will be made only by means of a prospectus, copies of which may be obtained from Morgan Stanley & Co. Incorporated, Attention: Prospectus Department, 180 Varick Street, New York, New York 10014 (email address: prospectus@morganstanley.com); or Goldman, Sachs & Co., Attention: Prospectus Department, 85 Broad Street, New York, New York 10004 (email address: prospectus-ny@ny.email.gs.com) or by calling (212) 902-1171; or UBS Investment Bank, Attention: Prospectus Department, 299 Park Avenue, New York, New York 10171 or by calling toll-free (888) 827-7275; or Barclays Capital Inc., c/o Broadridge, Integrated Distribution Services, 1155 Long Island Ave., Edgewood, New York 11717 (email address: barclaysprospectus@broadridge.com), or by calling toll-free (888) 603-5847.

About Emdeon

Emdeon Inc. is a leading provider of revenue and payment cycle management solutions, connecting payers, providers and patients in the U.S. healthcare system. The Company's product and service offerings integrate and automate key business and administrative functions of its payer and provider customers throughout the patient encounter, including pre-care patient eligibility and benefits verification, claims management and adjudication, payment distribution, payment posting and denial management and patient billing and payment collection. Through the use of the Company's comprehensive suite of products and services, which are designed to easily integrate with existing technology infrastructures, its customers are able to improve efficiency, reduce costs, increase cash flow and more efficiently manage the complex revenue and payment cycle process.

This press release contains forward-looking statements. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to the Company's operations and business environment, all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements include information concerning the Company's possible or assumed future results of operations, including descriptions of the Company's business strategy. These statements often include words such as "may," "will," "should," "believe," "expect," "anticipate," "intend," "plan," "estimate" or similar expressions. These statements are based on assumptions that the Company has made in light of its experience in the industry as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. Although the Company believes that these forward- looking statements are based on reasonable assumptions, you should be aware that many factors could affect the Company's actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. These factors are discussed in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections and elsewhere in the Company's registration statement.

You should keep in mind that any forward-looking statement made by the Company herein, or elsewhere, speaks only as of the date on which made. New risks and uncertainties come up from time to time, and it is impossible for the Company to predict these events or how they may affect it. The Company has no obligation to update any forward-looking statements after the date hereof, except as required by federal securities laws.


'/>"/>
SOURCE Emdeon
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Emdeon Business Services Extends Market Leadership With New Dental Eligibility Payers
2. HLTH Corporation Sells its Minority Interest in Emdeon Business Services to General Atlantic and Hellman & Friedman for $575 Million
3. General Atlantic and Hellman & Friedman Purchase HLTH Corporations Remaining Interest in Emdeon
4. Emdeon Business Services Names Miriam Paramore Senior Vice President of Corporate Strategy
5. Emdeon Business Services Processes One Billionth Pharmacy Claim for Department of Defense and the U.S. Military Health System
6. Emdeon Assistant Earns HFMAs Peer Review Designation
7. Nashvilles Emdeon Business Services to Co-Sponsor Democratic National Convention Health Policy Event
8. Emdeon Selected by the Maryland Hospital Association to Power the Maryland Transaction Data Interchange
9. Emdeon Convenes Industry Forum to Monitor Business Efficiency in Healthcare
10. Emdeon Announces Agreement to Acquire The Sentinel Group, a Leader in Healthcare Fraud and Abuse Management Services
11. Emdeon Assistant Earns HFMA Peer Reviewed Certification for Second Year in a Row
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting new patients ... in Lutz, FL. With the help of this highly-effective, yet convenient system, patients can ... more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear ...
(Date:4/25/2017)... ... ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace – from ... be heartened by the industry’s current surge. But another thing that unifies them is ... At last they can simply, safely and effectively end their aroma anguish thanks to ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® ... introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky ... horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s ...
(Date:4/24/2017)... ... April 24, 2017 , ... The Santana Telehealth Project was honored ... 2.0 — the American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. ... telemedicine to improve the lives of the poor and underserved in other parts of ...
(Date:4/24/2017)... ... ... Bright Pink , a national non-profit organization focusing on the prevention and early detection of ... is proud to announce Katie Thiede as their new Chief Executive Officer. In January, founder ... of the Board and launched a national search to find a visionary new leader to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
Breaking Medicine Technology: